South Korea to Approve Abortion Pills in 2027

Bright Seoul skyline illustrating South Korea’s plan to approve abortion pills for the first time — Seoul, South Korea. The image illustrates the national policy debate and does not depict a clinic or patient. Photo: Jiwon Kang/Unsplash.

South Korea struck down its criminal abortion ban in 2019. Yet for years afterward, one of the world’s most widely used methods of ending an early pregnancy remained unavailable through the country’s regulated medical system.

That is now set to change. The government says it intends to approve a two-drug abortion regimen—mifepristone followed by misoprostol—by the first quarter of 2027. The medicine would initially be available for pregnancies of up to nine weeks and, during the first two years, would be prescribed and dispensed directly by doctors.

The decision is a major practical shift in women’s healthcare. It is also an admission that decriminalization alone did not create a functioning system. South Korea removed criminal penalties after a constitutional ruling, but lawmakers failed to build a replacement framework governing medication, clinical standards, insurance coverage and physicians’ legal responsibilities.

As a result, patients have faced a paradox: abortion was no longer generally prosecuted under the old ban, but a standard medication option remained unapproved. Some sought pills through unverified online sellers; others relied on surgical procedures or on doctors prescribing misoprostol off-label.

On International Safe Abortion Day, September 28, South Korea’s experience carries a wider lesson. A legal right can exist on paper while access remains uncertain, expensive or medically fragmented. The next stage of the debate will concern not only whether abortion pills may be sold, but who can obtain them, under what conditions and at what cost.

What South Korea is proposing

The government announced that it aims to approve an application from a domestic company to import a combination pack of mifepristone and misoprostol. The first medicine blocks progesterone, a hormone needed for a pregnancy to continue; the second causes the uterus to contract and expel the pregnancy.

According to the Associated Press, Gender Equality and Family Minister Won Min-kyong described the plan as a step toward bringing abortion into the national healthcare system and reducing the risks created by unregulated access. President Lee Jae Myung had instructed officials in July to explore approval of the two-drug regimen.

The proposed nine-week limit is more restrictive than some medical guidelines and national systems, and the initial doctor-only dispensing model would be more controlled than mail-order or pharmacy access available elsewhere. Officials appear to be choosing a cautious rollout designed to reassure clinicians and the public while regulators gather experience.

That caution may make political approval easier. But it could also leave gaps for patients who live far from participating doctors, cannot take time away from work or fear stigma in small communities. The government has not yet resolved whether the national health insurance system will cover the medicine and associated care.

The seven-year gap after a landmark ruling

South Korea’s Constitutional Court ruled on April 11, 2019, that criminalizing abortion violated the Constitution. It gave the National Assembly until the end of 2020 to revise the law. When lawmakers missed that deadline, the criminal provisions became ineffective at the beginning of 2021.

The ruling transformed the legal landscape, but parliament never completed the corresponding health legislation. Research on post-decriminalization abortion care in South Korea has described persistent uncertainty involving medical standards, access, provider training and the cost of care.

The delay was not simply bureaucratic. Abortion remains culturally and politically contested in a society shaped by rapid demographic change, conservative Christian influence, Catholic opposition and a women’s movement that successfully challenged the old criminal law. South Korea also has one of the world’s lowest fertility rates, causing reproductive policy to be debated through the competing lenses of individual autonomy, public health and national population decline.

Those issues are often combined, but they are not identical. A government’s concern about falling births does not determine whether an individual pregnancy should continue. Conversely, approving medication does not settle every ethical dispute about fetal life or the appropriate role of the state.

Why approval changes medical safety

Mifepristone and misoprostol have been used internationally for decades. The World Health Organization’s abortion-care guideline includes evidence-based recommendations for medication abortion, while noting that countries vary in their legal and service-delivery systems.

Formal approval matters because it brings the drug supply, dosage, labeling, prescribing rules and follow-up care under regulatory oversight. Patients using pills obtained through unknown online sources may not know whether a product is genuine, stored correctly or supplied with accurate instructions. A regulated pathway also gives clinicians clearer responsibilities for assessing gestational age, identifying contraindications and treating uncommon complications.

That does not mean medication abortion is risk-free. Heavy bleeding, incomplete abortion and continuing pregnancy can require medical attention. South Korea’s obstetricians’ association has argued that approval must be accompanied by clinical safeguards and legal protection for practitioners. Those concerns deserve a specific regulatory answer rather than being dismissed as either resistance or alarmism.

At the same time, warnings should be proportionate to the evidence. Medical systems routinely manage drugs that carry possible complications. The policy question is whether risks are better addressed through regulated care and clear referral pathways or through continued restrictions that push some patients toward unverified channels.

Religious opposition remains influential

The Catholic Bishops’ Conference of Korea has expressed deep concern, arguing that the introduction of abortion pills could further weaken respect for human life. That position reflects longstanding Catholic teaching that abortion is morally impermissible.

Women’s-rights organizations take the opposite view. Korea Women’s Associations United called the announcement a first step toward safer pregnancy termination and urged faster access and national insurance coverage. Its emphasis on “first step” is important: drug approval alone will not ensure affordability, geographic availability, privacy or freedom from stigma.

A neutral policy analysis must distinguish moral opposition from medical regulation. Religious groups have a legitimate right to advocate against abortion and to support alternatives for pregnant women. But public rules in a pluralistic society must also account for the constitutional judgment, clinical evidence and the rights of people who do not share that religious belief.

The unresolved questions

The government still needs to answer several practical questions before the planned 2027 launch.

Cost: Will national insurance cover the pills, examinations and follow-up care, or will access depend on ability to pay?
Geography: Will patients outside major cities have enough participating clinicians?
Privacy: How will the system protect patients in communities where stigma remains strong?
Clinical rules: What training, emergency referral and follow-up standards will apply?
Provider law: Will parliament clearly protect clinicians acting within approved guidelines?
Conscience: How will the system accommodate objecting professionals without allowing refusal to eliminate access across an entire region?

These questions show why South Korea’s long delay matters. Courts can remove an unconstitutional punishment, but legislatures and health agencies must still build the system that makes a right usable. When they do not, uncertainty is transferred to patients and clinicians.

A test of whether decriminalization becomes healthcare

The planned approval does not end South Korea’s abortion debate. It moves that debate from a legal vacuum into the health system, where disagreements will focus on time limits, supervision, funding and professional responsibility.

Supporters will judge the policy by whether it reduces unsafe sourcing and expands meaningful choice. Opponents will continue to argue that easier access diminishes protection for unborn life. Doctors will demand clarity that allows them to care for patients without navigating contradictory rules.

The government’s cautious model may prove to be a workable compromise—or an unnecessarily restrictive bridge to a broader system. The decisive measure will be practical: whether a patient facing an early pregnancy can receive timely, evidence-based and affordable care without resorting to legal guesswork or an unverified seller.

Seven years after its constitutional turning point, South Korea is finally beginning to convert decriminalization into regulated medical access. That gap is the real story—and a warning that changing a law is not the same as changing what happens in a clinic.